Abstract
Contrast induced nephropathy (CIN) is an iatrogenic form of acute kidney injury (AKI) with variable but growing prevalence secondary to increased need for contrast administration during medical investigations such as coronary angiography. The mechanism of CIN is complex and poorly understood but is believed to be secondary to renal medullary hypoxia secondary to direct tubular toxicity from the contrast media and vasoconstriction. N-acetylcysteine (NAC) an antioxidant and vasodilator, has shown promising results in early investigations but failed to demonstrate consistent results in subsequent clinical trials and their meta-analysis. In this review we aim to discuss pharmacological properties of NAC and appraise the literature regarding the use of NAC for the prevention of CIN after coronary angiography.
Keywords: Acetylcysteine/therapeutic use, angiography/adverse effects, contrast media/adverse effects, humans, kidney diseases/chemically induced, kidney diseases/prevention & control.
Current Drug Therapy
Title:Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Volume: 9 Issue: 2
Author(s): Mayank K. Mittal, Kanupriya Jain, Harsh Agrawal, Poonam Velagapudi, Sonal Dhuper and Arun Kumar
Affiliation:
Keywords: Acetylcysteine/therapeutic use, angiography/adverse effects, contrast media/adverse effects, humans, kidney diseases/chemically induced, kidney diseases/prevention & control.
Abstract: Contrast induced nephropathy (CIN) is an iatrogenic form of acute kidney injury (AKI) with variable but growing prevalence secondary to increased need for contrast administration during medical investigations such as coronary angiography. The mechanism of CIN is complex and poorly understood but is believed to be secondary to renal medullary hypoxia secondary to direct tubular toxicity from the contrast media and vasoconstriction. N-acetylcysteine (NAC) an antioxidant and vasodilator, has shown promising results in early investigations but failed to demonstrate consistent results in subsequent clinical trials and their meta-analysis. In this review we aim to discuss pharmacological properties of NAC and appraise the literature regarding the use of NAC for the prevention of CIN after coronary angiography.
Export Options
About this article
Cite this article as:
K. Mittal Mayank, Jain Kanupriya, Agrawal Harsh, Velagapudi Poonam, Dhuper Sonal and Kumar Arun, Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents, Current Drug Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574885509666140716171925
DOI https://dx.doi.org/10.2174/1574885509666140716171925 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heart Rate as a Therapeutic Target in Angina Pectoris
Current Pharmaceutical Design Lone Atrial Fibrillation: Electrophysiology, Risk Factors, Catheter Ablation and Other Non-pharmacologic Treatments
Current Pharmaceutical Design α2-Antiplasmin on Cardiovascular Diseases
Current Pharmaceutical Design Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology Myocardial Cellular Damage and Antioxidant Status in Off-Pump Versus On-Pump Coronary Artery Bypass Grafting - A Prospective Study
Vascular Disease Prevention (Discontinued) Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets
Current Pharmaceutical Design The Protective Effects of Levosimendan on Ischemia/Reperfusion Injury and Apoptosis
Recent Patents on Cardiovascular Drug Discovery Lessons from Leptins Molecular Biology: Potential Therapeutic Actions of Recombinant Leptin and Leptin-Related Compounds
Mini-Reviews in Medicinal Chemistry Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine Inhibition of G Protein-Activated Inwardly Rectifying K+ Channels by Phencyclidine
Current Neuropharmacology Non-histone Methylation of SET7/9 and its Biological Functions
Recent Patents on Anti-Cancer Drug Discovery Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Exogenous Factors from Venomous and Hematophagous Animals in Drugs and Diagnostic Developments for Cardiovascular and Neurovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Geriatric Depression - Review for Primary Care
Current Psychiatry Reviews New Anti-Thrombotic Drugs for Stroke Prevention
Current Vascular Pharmacology